Issued 2026-08-13 at $28.96 · now $28.86 (2026-08-13, −0.3% since)
Based on its own history, a month from the 2026-08-13 close, RCUS has typically landed between $22.70 and $37.51 — a range of −21.6% to +29.5% from the issuance price $28.96.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
2,093 overlapping 1 month windows · 2018-03-15 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($28.96) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where RCUS has typically landed a month from the 2026-08-13 close of $28.96 — the range is history, not a prediction.
- now $28.86 (-0.3%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $29.06 (+0.4%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $25.77–$32.35
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $22.7–$37.51
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2022-12-05 | −45.3% | −45.3% | +0.0% |
| 2022-04-11 | −45.0% | −45.0% | +2.0% |
| 2022-12-07 | −44.3% | −44.3% | +6.9% |
| 3 best | |||
| 2020-03-19 | +196.1% | +0.0% | +200.8% |
| 2020-03-18 | +191.8% | −3.0% | +191.8% |
| 2020-03-20 | +180.2% | +0.0% | +186.5% |
2,093 overlapping windows · 2018-03-15 – 2026-08-13 · not cherry-picked
Pending catalysts
- January 2027 — Trial primary completion: Phase 2 primary completion: A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies (source, as of 2026-08-14)
- May 2027 — Trial primary completion: Phase 2 primary completion: Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (source, as of 2026-08-14)
- April 2028 — Trial primary completion: Phase 3 primary completion: Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma (source, as of 2026-08-14)
- 2030-11-30 — Trial primary completion: Phase 3 primary completion: Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~9 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.